Abstract
The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data. The Journal of Rheumatology
| Original language | English |
|---|---|
| Pages (from-to) | 30-32 |
| Number of pages | 3 |
| Journal | Journal of Rheumatology |
| Volume | 93 |
| DOIs | |
| Publication status | Published - Nov 1 2015 |
Fingerprint
Keywords
- Adverse events
- Biological drugs
- Psoriatic arthritis
- Registries
ASJC Scopus subject areas
- Rheumatology
- Immunology
- Immunology and Allergy
Cite this
Psoriatic arthritis registries. / Sarzi-Puttini, Piercarlo; Varisco, Valentina; Ditto, Maria Chiara; Benucci, Maurizio; Atzeni, Fabiola.
In: Journal of Rheumatology, Vol. 93, 01.11.2015, p. 30-32.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Psoriatic arthritis registries
AU - Sarzi-Puttini, Piercarlo
AU - Varisco, Valentina
AU - Ditto, Maria Chiara
AU - Benucci, Maurizio
AU - Atzeni, Fabiola
PY - 2015/11/1
Y1 - 2015/11/1
N2 - The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data. The Journal of Rheumatology
AB - The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data. The Journal of Rheumatology
KW - Adverse events
KW - Biological drugs
KW - Psoriatic arthritis
KW - Registries
UR - http://www.scopus.com/inward/record.url?scp=84962859545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962859545&partnerID=8YFLogxK
U2 - 10.3899/jrheum.150631
DO - 10.3899/jrheum.150631
M3 - Article
C2 - 26523052
AN - SCOPUS:84962859545
VL - 93
SP - 30
EP - 32
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
ER -